Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of investigational RSV/hMPV combination and hMPV vaccines in younger and older adults
jRCT2031260633Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, single-blind trial of mRNA-1365 in respiratory syncytial virus disease (RSV) and human metapneumovirus infection (HMPV) (17 arms), sponsored by GSK. Primary endpoints: Number of Participants Reporting Solicited Administration Site Events, Number of Participants Reporting Solicited Systemic Events and 5 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
mRNA-1365
03
Conditions
respiratory syncytial virus disease (RSV)human metapneumovirus infection (HMPV)
Beyond the preview
Go deeper on jRCT2031260633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260633.